Northwire Canada EditionThursday, September 3, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4539.90 +2.8% SILVER 67.58 +3.2% COPPER 6.67 +1.2% OIL 91.30 +0.3% PALLADIUM 1436.00 +5.5% COCO 0.300 +0.0% CPL 0.195 −11.4% FUU 0.145 −3.3% NUAG 9.25 −0.1% FDY 5.14 −1.9% GRZ 6.66 +0.1% TES 0.110 +10.0% MINK 0.100 +0.0% CAN 0.080 +0.0% ELEF 0.135 −12.9% LVG 0.305 −3.2% GAL 0.640 −4.5% WRX 0.040 +0.0% PHD 0.055 +22.2% DYG 0.135 +8.0% GR 0.075 +7.1% GOLD 4539.90 +2.8% SILVER 67.58 +3.2% COPPER 6.67 +1.2% OIL 91.30 +0.3% PALLADIUM 1436.00 +5.5% COCO 0.300 +0.0% CPL 0.195 −11.4% FUU 0.145 −3.3% NUAG 9.25 −0.1% FDY 5.14 −1.9% GRZ 6.66 +0.1% TES 0.110 +10.0% MINK 0.100 +0.0% CAN 0.080 +0.0% ELEF 0.135 −12.9% LVG 0.305 −3.2% GAL 0.640 −4.5% WRX 0.040 +0.0% PHD 0.055 +22.2% DYG 0.135 +8.0% GR 0.075 +7.1%
Regulatory Routine +

PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness

Strategic Alignment with Federal Psychedelic Mandate

By The Northwire Desk — AI Analysis Apr 21, 2026 · 08:01 PHRM · 0.11 PharmaTher Holdings Ltd.
Executive Summary
  • The most recent news release dated April 21, 2026, highlights a strategic opportunity for PharmaTher following a new U.S. Executive Order signed on April 18, 2026.
  • The order focuses on accelerating medical treatments for serious mental illness using psychedelic drugs and emphasizes data sharing between the FDA, HHS, and private sector.
  • PharmaTher believes this regulatory environment strengthens the strategic value of its retained ketamine portfolio, including microneedle patch programs (KetaVault) and specialty indications like Parkinson's disease and ALS.
  • The company notes ongoing economic exposure from a previously sold FDA-approved ketamine ANDA (#217858), which could generate over US$25 million through milestones and profit-sharing.
  • This follows previous news on April 20 regarding the positioning of microneedle patch platforms to benefit from U.S. catalysts in psychedelics and peptides.
Material Impact
  • The Executive Order represents a macro-level regulatory shift that validates PharmaTher's strategic focus on ketamine and psychedelic delivery technologies.
  • However, the material financial impact is currently limited as the company sold its primary generic asset (ANDA) to another entity; they retain proprietary programs which are still in development.
  • The news does not announce new revenue, financing, or clinical trial results that would immediately alter cash flow projections.
  • Given the stock's history of declining despite previous "positive" announcements regarding the ANDA sale and GLP-1 expansion, this regulatory commentary is viewed as incremental rather than transformative.
  • The market reaction (price bounce from $0.06 to $0.11 in late April) suggests some investor interest but remains within a broader downtrend context.
PHRM · Price
Company Overview
  • PharmaTher Holdings Ltd. is a biotechnology company focused on ketamine-based therapies and microneedle patch delivery platforms.
  • Flagship Project: The Ketamine Microneedle Patch program (PharmaPatch) designed for controlled, sustained delivery to reduce treatment burden.
  • Secondary Projects: Long-acting injectable ketamine franchise (LAI), GLP-1 obesity patches, therapeutic peptide delivery (BPC-157, GHK-Cu), and AI-driven discovery platform (KetAImine).
  • The company previously achieved FDA approval for a generic Ketamine ANDA (#217858) which was sold to a sterile-injectables pharmaceutical company.
Read the original news release →

More from PharmaTher Holdings Ltd.

May 27, 2026 · 08:01

PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines

Other May 13, 2026 · 10:12

PharmaTher Explores Hantavirus Treatment Amidst Stock Plunge and Strategic Pivots

Other May 13, 2026 · 10:08

PharmaTher Advances Antiviral Pipeline with Hantavirus Candidate Amidst Ketamine Monetization

Other Apr 20, 2026 · 08:01

PharmaTher Seeks Regulatory Tailwinds Amidst Price Slump

Production / Operations Apr 16, 2026 · 08:01

PharmaTher Peptide Strategy Faces Regulatory Hurdles Amidst 89% Stock Decline

Regulatory Apr 13, 2026 · 08:01

PharmaTher Files Peptide Patch Patent as Stock Nears All-Time Lows Despite Pipeline Expansion

M&A / Property